11.86 (-%)
As of Dec 03, 2024
Source:
Delcath Systems, Inc is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our lead product candidate, the HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), or HEPZATO, is a drug/device combination product designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Country | United States |
Headquarters | new york, new york |
Phone Number | (212) 489-2100 |
Industry | manufacturing |
CEO | Gerard Michel |
Website | delcath.com |